
What is Claimed:

1. A compound, or pharmaceutically acceptable salt thereof, having a structure of Formula I:



(I),

wherein

X is C_{1-6}alkylene, C_{2-6}alkenylene, C_{2-6}alkynylene, C_{3-10} cycloalkylene, or 4-6 membered heterocyclene, and X is optionally substituted with 1-5 groups independently selected from R^3 and R^4;

Y is C_{0-6} alkylene, C_{3-6} alkenylene, C_{3-6} alkynylene, and Y is optionally substituted with 1-3 groups independently selected from halo, $N(R^3)_2$, and R^3;

A is C_{6-10} aryl or 5-10 membered heteroaryl having 1-4 heteroatoms selected from N, O, and S, and A is optionally substituted with 1 to 3 R^4;

B is C_{6-10} aryl, 5-10 membered heteroaryl having 1-4 heteroatoms selected from N, O, and S, 3-8 membered cycloalkyl ring, or a 4-10 membered heterocycle having 1-3 heteroatoms selected from N, O, and S, and B is optionally substituted with 1 to 3 R^5;

Z is O, S, NH, or NR^3;

R^1 and R^2 are each independently C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-6} alkynyl, or C_{3-6} cycloalkyl, or R^1 and R^2 together with the carbon atom to which they are attached form a 4-8 membered cycloalkyl or heterocycle, wherein the heterocycle has 1 or 2 ring heteroatoms selected from O, S, and N, and wherein said cycloalkyl or heterocycle is optionally substituted with 1-2 R^4;

each R^3 is independently OH, C_{1-6} alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, phenyl, O-phenyl, benzyl, O-benzyl, C_{3-6}cycloalkyl, 4-10 membered heterocycle having 1 to 4 heteroatoms selected from N, O, and S, or $(O)_{0-1}$-5-10 membered heteroaryl having 1 to 3 heteroatoms selected from N, O, and S, or two R^3 taken together with the atom(s) to which they are attached form a C_{3-6} cycloalkyl (e.g., C_{4-6} cycloalkenyl), or 4-6 membered heterocycle having one heteroatom selected from N, O and S;

each R^4 and R^5 is independently halo, NO_2, oxo, cyano, C_{1-4} alkyl, C_{1-4}haloalkyl (e.g., CF_3, CHF_2), C_{1-4}alkoxy, C_{1-4}haloalkoxy (e.g., OCF_3, $OCHF_2$), C_{1-4}thioalkoxy, C_{2-4}alkenyl, C_{2-4}alkynyl, CHO, $C(=O)R^6$, $C(=O)N(R^6)_2$, $S(O)_{0-2}R^6$, $SO_2N(R^6)_2$, NH_2, NHR^6, $N(R^6)_2$, NR^7COR^6, $NR^7SO_2R^6$, $P(=O)(R^6)_2$, C_{3-6}cycloalkyl, 4-10 membered heterocycle having 1 to 4 heteroatoms selected from N, O, and S (e.g., oxetanyl, oxetanyloxy, oxetanylamino, oxolanyl, oxolanyloxy, oxolanylamino, oxanyl oxanyloxy, oxanylamino, oxepanyl, oxepanyloxy, oxepanylamino, azetidinyl, azetidinyloxy, azetidylamino, pyrrolidinyl, pyrolidinyloxy, pyrrolidinylamino, piperidinyl, piperidinyloxy, piperidinylamino, azepanyl,

azepanyloxy, azepanylamino, dioxolanyl, dioxanyl, morpholino, thiomorpholino, thiomorpholino-S,S-dioxide, piperazinyl, dioxepanyl, dioxepanyloxy, dioxepanylamino, oxazepanyl, oxazepanyloxy, oxazepanylamino, diazepanyl, diazepanyloxy, or diazepanylamino);

each R^6 is independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} alkenyl, C_{3-6} alkynyl, $COOR^7$, $CON(R^7)_2$, C_{0-3}alkylene-C_{3-8}cycloalkyl, C_{0-3}alkylene-C_{6-10}aryl, C_{0-3}alkylene-(4-10 membered heterocycle having 1-4 heteroatoms selected from N, O, and S), or C_{0-3}alkylene-(5-10 membered heteroaryl having 1-4 heteroatoms selected from N, O, and S), wherein the aryl, heterocyle, or heteroaryl is optionally substituted with 1 to 3 R^7; and

each R^7 is independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} alkenyl, C_{3-6} alkynyl, C_{1-4}alkoxy, or C_{1-4}haloalkoxy.


2. The compound or salt of claim 1, wherein R^1 and R^2 are each independently C_{1-6} alkyl.

3. The compound or salt of claim 2, wherein R^1 and R^2 are each methyl.

4. The compound or salt of claim 1, wherein R^1 and R^2 together with the carbon atom to which they are attached form a 4-8 membered cycloalkyl or heterocycle.

5. The compound or salt of claim 4, wherein R^1 and R^2 together with the carbon atom to which they are attached form a 5 or 6 membered cycloalkyl or heterocycle.

6. The compound or salt of claim 5, wherein R^1 and R^2 together with the carbon atom to which they are attached form a cyclohexyl ring.

7. The compound or salt of claim 5, wherein R^1 and R^2 together with the carbon atom to which they are attached form a heterocycle having the structure: 

, where * indicates the point of attachment to the rest of the compound of Formula I.

8. The compound or salt of any one of claims 1 to 7, wherein A is C_{6-10} aryl.

9. The compound or salt of claim 8, wherein A is phenyl.

10. The compound or salt of any one of claims 1 to 9, wherein B is C_{6-10} aryl.

11. The compound or salt of claim 10, wherein B is phenyl.

12. The compound or salt of any one of claims 1 to 9, wherein B is 5-10 membered heteroaryl having 1-4 heteroatoms selected from N, O, and S.

13. The compound or salt of claim 12, wherein B is pyridinyl.


14. The compound or salt of claim 12, wherein B is quinolinyl.

15. The compound or salt of any one of claims 1 to 9, wherein B is 3-8 membered cycloalkyl.

16. The compound or salt of claim 15, wherein B is 5 or 6 membered cycloalkyl.

17. The compound or salt of any one of claims 1 to 9, wherein B is 3-12 membered heterocycle having 1-3 ring heteroatoms selected from O, S, and N.

18. The compound or salt of any one of claims 1 to 17, wherein A is substituted with one R^4.

19. The compound or salt of claim 18, wherein A has the structure: 

.

20. The compound or salt of any one of claims 1 to 17, wherein A is substituted with two R^4.

21. The compound or salt of any one of claims 1 to 20, wherein at least one R^4 is C_{1-6} alkyl.

22. The compound or salt of claim 21, wherein is at least one R^4 is methyl.

23. The compound or salt of any one of claims 1 to 22, wherein at least one R^4 is halo.

24. The compound or salt of claim 23, wherein R^4 is bromo.

25. The compound or salt of claim 23 or 24, wherein R^4 is chloro.


26. The compound or salt of claim 23, 24, or 25, wherein R^4 is fluoro.

27. The compound or salt of any one of claims 1 to 26, wherein at least one R^4 is C_{1-6} alkoxy.

28. The compound or salt of claim 27, wherein at least one R^4 is methoxy.

29. The compound or salt of any one of claims 1 to 28, wherein B is substituted with one R^5.

30. The compound or salt of any one of claims 1 to 28, wherein B is substituted with two R^5.

31. The compound of claim 30, wherein B has the structure 

.

32. The compound or salt of any one of claims 1 to 31, wherein at least one R^5 is halo.

33. The compound or salt of claim 32, wherein at least one R^5 is fluoro or chloro.

34. The compound or salt of claim 30 or 32, wherein one R^5 is fluoro and the other R^5 is chloro.

35. The compound or salt of any one of claims 1 to 34, wherein at least one R^5 is C_{1-6} alkoxy.

36. The compound or salt of claim 35, wherein at least one R^5 is methoxy.

37. The compound or salt of any one of claims 30 to 36, wherein one R^5 is halo and the other R^5 is C_{1-6} alkoxy.

38. The compound or salt of claim 37, wherein one R^5 is chloro and the other R^5 is methoxy.

39. The compound or salt of any one of claims 1 to 38, wherein X is C_{1-6}alkylene.

40. The compound or salt of any one of claims 1 to 38, wherein X is C_{2-6}alkenylene or C_{2-6}alkynylene.

41. The compound or salt of any one of claims 1 to 38, wherein X is C_{3-10} cycloalkylene, or 4-6 membered heterocyclene.

42. The compound or salt of any one of claims 1 to 41, wherein Y is a bond.

43. The compound or salt of any one of claims 1 to 41, wherein Y is C_{1-6}alkylene.

44. The compound or salt of any one of claims 1 to 41, wherein Y is C_{2-6}alkenylene or C_{2-6}alkynylene.

45. The compound or salt of any one of claims 1 to 44, wherein Z is O.

46. The compound or salt of any one of claims 1 to 44, wherein Z is S.

47. The compound or salt of any one of claims 1 to 44, wherein Z is NH or NR^3.

48. The compound or salt of any one of claims 1 to 47, wherein R^3 is H.

49. A pharmaceutical composition comprising the compound or salt of any one of claims 1 to 48 and a pharmaceutically acceptable carrier or excipient.

50. A method of modulating EGFR comprising administering to a subject in need thereof a therapeutically effective amount of the compound or salt of any one of claims 1 to 48.

51. A method of modulating KRAS comprising administering to a subject in need thereof a therapeutically effective amount of the compound or salt of any one of claims 1 to 48.

52. A method of modulating cMET comprising administering to a subject in need thereof a therapeutically effective amount of the compound or salt of any one of claims 1 to 48.

53. A method of modulating BRAF comprising administering to a subject in need thereof a therapeutically effective amount of the compound or salt of any one of claims 1 to 48.

54. A method of treating cancer in a subject who suffers therefrom, comprising administering to the subject a therapeutically effective amount of the compound or salt of any one of claims 1 to 48.

55. The method of claim 54, wherein the cancer is acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vulva, leukemia (e.g., chronic lymphocytic leukemia), chronic myeloid cancer, colon cancer, esophageal cancer, cervical cancer, gastrointestinal carcinoid tumor, Hodgkin lymphoma, hypopharynx cancer, kidney cancer, larynx cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharynx cancer, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, peritoneum, omentum, and mesentery cancer, pharynx cancer, prostate cancer, rectal cancer, renal cancer (e.g., renal cell carcinoma (RCC)), small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, ureter cancer, or urinary bladder cancer.

56. The method of claim 54, wherein the cancer is selected from lung cancer, colorectal cancer, glioblastoma, and head and neck cancer.

57. The method of claim 54, wherein the cancer is melanoma, colon cancer, renal cancer, leukemia, or breast cancer.

58. The method of any one of claims 54 to 57, wherein the cancer is osimertinib-resistant cancer.

59. The method of any one of claims 54 to 58, wherein the subject is human.